Comparative analysis of MECT treatment on refractory schizophrenia

OBJECTIVE: To investigate the MECT (MECT) combined clozapine difficult clinical effect and safety of active schizophrenia METHODS: 71 patients with refractory schizophrenia were randomly divided into two groups, study group of 36 patients in the more small application on the basis of joint use of clozapine MECT treatment control group of 35 patients, only clozapine therapy;. for a 12-week clinical controlled study was before treatment and the use of positive weekend of 8 and 12 and negative Syndrome scale (PANSS) and symptom scale (TESS) to evaluate the clinical efficacy and adverse reactions: after 12 weeks of treatment, clinical research group, the total effective rate was 61.8% in the control group clinical total effective rate was 29.1%. , there was a significant difference (P <0.05 or P <0.01) groups; Study group lethargy, salivation, constipation, weight gain, abnormal electrocardiogram, leukopenia and other factors less than the control group, the difference was significant (P <0.01 or P <0.05) CONCLUSION: MECT combined clozapine effective refractory schizophrenia, mild adverse reactions, suitable for clinical use.